0001123292-25-000336.txt : 20250804 0001123292-25-000336.hdr.sgml : 20250804 20250804120447 ACCESSION NUMBER: 0001123292-25-000336 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20250804 DATE AS OF CHANGE: 20250804 EFFECTIVENESS DATE: 20250804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp. CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 453215903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-553575 FILM NUMBER: 251178840 BUSINESS ADDRESS: STREET 1: 411 SWEDELAND ROAD STREET 2: SUITE 23-1080 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 411 SWEDELAND ROAD STREET 2: SUITE 23-1080 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20111019 D 1 primary_doc.xml X0708 D LIVE 0001533040 Phio Pharmaceuticals Corp. 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 (508) 767-3861 DELAWARE Rxi Pharmaceuticals Corporation RXi Pharmaceuticals Corp Corporation true Robert J. Bitterman 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 Director Executive Officer Patricia A. Bradford 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 Director Robert Ferrara 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 Director Jonathan Freeman 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 Director Curtis Lockshin, Ph.D. 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 Director Lisa Carson 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 Executive Officer David H. Deming 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 Director Biotechnology Decline to Disclose 06b false 2025-07-28 false true true false 0 5080826 232149 4848677 The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b). false 2 261753 0 In connection with the offering, the placement agent received $261,753 and warrants to purchase up to 69,645 shares of common stock, 7,500 of which are exercisable at $2.8125 per share and 62,145 of which are exercisable at $3.4188 per share. 0 false Phio Pharmaceuticals Corp. /s/ Robert J. Bitterman Robert J. Bitterman President and Chief Executive Officer 2025-08-04